Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2015 16:05 ET | Source: Melinta Therapeutics, Inc.

Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents

CHAPEL HILL, N.C., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
December 08, 2015 07:00 ET | Source: Melinta Therapeutics, Inc.

Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta(TM) in Acute Bacterial Skin and Skin Structure Infections

CHAPEL HILL, N.C., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company developing antibiotics to meet critical medical needs in the treatment of...
November 11, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Anti-NASH Data for Solithromycin at The Liver Meeting(R) 2015

CHAPEL HILL, N.C., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
November 10, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present at Two Upcoming Investor Conferences

CHAPEL HILL, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 23, 2015 09:24 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Solithromycin Oral Data at CHEST 2015

CHAPEL HILL, N.C., Oct. 23, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 22, 2015 07:00 ET | Source: Melinta Therapeutics, Inc.

Cempra Reports Third Quarter 2015 Financial Results and Provides Corporate Update

CHAPEL HILL, N.C., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 19, 2015 08:00 ET | Source: Melinta Therapeutics, Inc.

Cempra to Report Third Quarter 2015 Financial Results

CHAPEL HILL, N.C., Oct. 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
October 16, 2015 07:00 ET | Source: Melinta Therapeutics, Inc.

Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia

Solithromycin Met All FDA Primary Objectives of Non-Inferiority Compared to Moxifloxacin Two Phase 3 Trials Required by the FDA and the EMA for CABP Regulatory Filings Now Complete Rolling NDA...
October 05, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Solithromycin Data at ID Week 2015

CHAPEL HILL, N.C., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
September 24, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Solithromycin Data in COPD Patient Subgroup at European Respiratory Society International Congress

CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right